Sith Sathornsumetee

10.8k total citations · 4 hit papers
89 papers, 7.5k citations indexed

About

Sith Sathornsumetee is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Sith Sathornsumetee has authored 89 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Genetics, 24 papers in Pulmonary and Respiratory Medicine and 23 papers in Oncology. Recurrent topics in Sith Sathornsumetee's work include Glioma Diagnosis and Treatment (60 papers), Cancer, Hypoxia, and Metabolism (19 papers) and Brain Metastases and Treatment (17 papers). Sith Sathornsumetee is often cited by papers focused on Glioma Diagnosis and Treatment (60 papers), Cancer, Hypoxia, and Metabolism (19 papers) and Brain Metastases and Treatment (17 papers). Sith Sathornsumetee collaborates with scholars based in United States, Thailand and Canada. Sith Sathornsumetee's co-authors include Jeremy N. Rich, David A. Reardon, Roger E. McLendon, Darell D. Bigner, Annick Desjardins, James J. Vredenburgh, Henry S. Friedman, Anita B. Hjelmeland, James E. Herndon and Jennifer A. Quinn and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Nature Neuroscience.

In The Last Decade

Sith Sathornsumetee

87 papers receiving 7.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme

2007 1.0k citations James J. Vredenburgh, Annick Desjardins et al. profile →
Hypoxia-Inducible Factors Regulate Tumorigenic Capacity of Glioma Stem Cells

2009 1.0k citations Shideng Bao, Sith Sathornsumetee et al. profile →
Stem Cell–like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor

2006 1.0k citations Shideng Bao, Qiulian Wu et al. Cancer Research profile →
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

2007 815 citations James J. Vredenburgh, Annick Desjardins et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Sith Sathornsumetee

Since Specialization

Citations

This map shows the geographic impact of Sith Sathornsumetee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sith Sathornsumetee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sith Sathornsumetee more than expected).

Fields of papers citing papers by Sith Sathornsumetee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sith Sathornsumetee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sith Sathornsumetee. The network helps show where Sith Sathornsumetee may publish in the future.

Co-authorship network of co-authors of Sith Sathornsumetee

This figure shows the co-authorship network connecting the top 25 collaborators of Sith Sathornsumetee. A scholar is included among the top collaborators of Sith Sathornsumetee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sith Sathornsumetee. Sith Sathornsumetee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	GLIMMERS: glioma molecular markers exploration using long-read sequencing 2024 ·Bioinformatics Advances ·(unknown), (unknown), Bhoom Suktitipat, Manop Pithukpakorn, Sith Sathornsumetee, Thidathip Wongsurawat, Piroon Jenjaroenpun	0
2	Exploiting nanopore sequencing for characterization and grading of IDH‐mutant gliomas 2023 ·Brain Pathology ·Thidathip Wongsurawat, Piroon Jenjaroenpun, (unknown), (unknown), (unknown), Azemat Jamshidi‐Parsian, Gunnar Boysen, Prapat Suriyaphol, Bhoom Suktitipat, (unknown), Pornsuk Cheunsuchon, Jantima Tanboon, Intawat Nookaew, Sith Sathornsumetee	8
3	Assessment of therapeutic effect of CD20-targeted immunoliposome in primary central nervous system lymphoma 2022 ·Biomedicine & Pharmacotherapy ·(unknown), Paweena Dana, (unknown), (unknown), (unknown), Nattika Saengkrit, Sith Sathornsumetee	8
4	Simplified approach for pathological diagnosis of diffuse gliomas in adult patients 2021 ·Pathology - Research and Practice ·(unknown), (unknown), (unknown), (unknown), Atthaporn Boongird, Sith Sathornsumetee, (unknown), Pornsuk Cheunsuchon, Jantima Tanboon, Paul S. Thorner, Shanop Shuangshoti	7
5	Nanostructured lipid base carrier for specific delivery of garlic oil through blood brain barrier against aggressiveness of glioma 2021 ·Journal of Drug Delivery Science and Technology ·Paweena Dana, Jakarwan Yostawonkul, (unknown), (unknown), (unknown), Sith Sathornsumetee, Nattika Saengkrit	15
6	Neuro-Oncology: An Emerging Neurologic Subspecialty in Thailand 2020 ·SHILAP Revista de lepidopterología ·Sith Sathornsumetee	1
7	Phase 2, open-label study of ceritinib in patients (pts) with advanced non-lung solid tumors and hematological malignancies characterized by genetic abnormalities in anaplastic lymphoma kinase (ALK) using a flexible adaptive design: ASCEND-10 2016 ·Annals of Oncology ·(unknown), Jordi Rodón, Enrique Grande Pulido, Sun Young Rha, Sith Sathornsumetee, (unknown), E. Eigendorff, (unknown), Santosh Sutradhar, Barnali Pramanik, T.M. Kim	1
8	Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma 2012 ·Journal of Neuro-Oncology ·David A. Reardon, James J. Vredenburgh, Annick Desjardins, Katherine B. Peters, Sith Sathornsumetee, Stevie Threatt, John H. Sampson, James E. Herndon, April Coan, Frances McSherry, Jeremy N. Rich, Roger E. McLendon, Steven Zhang, Henry S. Friedman	28
9	Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low‐grade glioma 2012 ·Cancer ·David A. Reardon, Annick Desjardins, James J. Vredenburgh, James E. Herndon, April Coan, Sridharan Gururangan, Katherine B. Peters, Roger E. McLendon, Sith Sathornsumetee, Jeremy N. Rich, Eric Lipp, (unknown), Henry S. Friedman	24
10	Targeting Cancer Stem Cells through L1CAM Suppresses Glioma Growth 2008 ·Cancer Research ·Shideng Bao, Qiulian Wu, Zhizhong Li, Sith Sathornsumetee, Hui Wang, Roger E. McLendon, Anita B. Hjelmeland, Jeremy N. Rich	327
11	Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas 2008 ·Clinical Cancer Research ·Annick Desjardins, David A. Reardon, James E. Herndon, Jennifer Marcello, Jennifer A. Quinn, Jeremy N. Rich, Sith Sathornsumetee, Sridharan Gururangan, John H. Sampson, Leighann Bailey, Darell D. Bigner, Allan H. Friedman, Henry S. Friedman, James J. Vredenburgh	130
12	Molecularly targeted therapy for malignant glioma 2007 ·Cancer ·Sith Sathornsumetee, David A. Reardon, Annick Desjardins, Jennifer A. Quinn, James J. Vredenburgh, Jeremy N. Rich	250
13	Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge 2007 ·Current Pharmaceutical Design ·Sith Sathornsumetee, Jeremy N. Rich	37
14	Stem Cell–like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor breakdown → 2006 ·Cancer Research ·Shideng Bao, Qiulian Wu, Sith Sathornsumetee, Yueling Hao, Zhizhong Li, Anita B. Hjelmeland, Qing Shi, Roger E. McLendon, Darell D. Bigner, Jeremy N. Rich	1022
15	Vandetanib (ZD6474), a novel multitargeted kinase inhibitor, incancer therapy 2006 ·Drugs of today ·Sith Sathornsumetee, Jeremy N. Rich	27
16	New approaches to primary brain tumor treatment 2006 ·Anti-Cancer Drugs ·Sith Sathornsumetee, Jeremy N. Rich	49
17	Parry-Romberg syndrome with fatal brain stem involvement 2005 ·The Journal of Pediatrics ·Sith Sathornsumetee, Laura E. Schanberg, Egla Rabinovich, Darrell V. Lewis, Pedro Weisleder	27
18	Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma 2005 ·Cancer ·David A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, Annick Desjardins, James J. Vredenburgh, Sridharan Gururangan, Sith Sathornsumetee, Michael Badruddoja, Roger E. McLendon, James Provenzale, James E. Herndon, Jeannette M. Dowell, (unknown), Herbert B. Newton, Allan H. Friedman, Henry S. Friedman	59
19	Friday night palsy: an unusual case of brachial plexus neuropathy 2005 ·Clinical Neurology and Neurosurgery ·Sith Sathornsumetee, Joel C. Morgenlander	3
20	Quantitative Ultrastructural Analysis of a Single Spinal Cord Demyelinated Lesion Predicts Total Lesion Load, Axonal Loss, and Neurological Dysfunction in a Murine Model of Multiple Sclerosis 2000 ·American Journal Of Pathology ·Sith Sathornsumetee, Dorian B. McGavern, Daren Ure, Moses Rodriguez	46

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact